Executive Summary

GLP-1 receptor agonists (GLP-1 RAs) represent a transformative class of incretin-based therapeutics originally developed for type 2 diabetes (T2D), now proven to yield robust, clinically meaningful weight loss. Mechanisms extend beyond glycemic control to include central appetite suppression, delayed gastric emptying, and modulation of energy expenditure. High-evidence data—from phase 3 randomized controlled trials (RCTs) to long-term post-marketing studies—demonstrate weight reductions of 5–15% with newer agents (e.g., semaglutide 2.4 mg weekly, tirzepatide), rivaling metabolic surgery in magnitude. This article provides a rigorous review of GLP-1 RA pharmacology, clinical trial evidence for weight loss, comparative efficacy, safety profiles, and practical considerations for integration into obesity medicine practice.

1. Physiologic Basis of GLP-1 Signaling

GLP-1 is an intestinal incretin hormone secreted by enteroendocrine L-cells in response to nutrient ingestion (particularly fats and carbohydrates). Its endogenous half-life is ~2 minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4) and renal clearance [1]. Physiologic actions include:

• Enhanced glucose-dependent insulin secretion
• Suppressed glucagon release
• Delayed gastric emptying
• Increased satiation/satiety via action on hypothalamic and brainstem GLP-1 receptors
• Potential modulation of energy expenditure and brown adipose tissue activity [2,3]

GLP-1 RAs resist DPP-4 degradation and exhibit extended half-lives (hours to days), enabling once-daily or once-weekly dosing.

2. Mechanisms Underlying Weight Loss

While all GLP-1 RAs promote weight loss, the magnitude correlates with receptor affinity, half-life, and potential off-target effects (e.g., dual GIP/GLP-1 agonism). Key pathways include:

2.1 Central Nervous System Effects

GLP-1 crosses the blood–brain barrier via active transport [4] and binds receptors in:

• Area postrema (nucleus tractus solitarii): Mediates satiety and nausea
• Hypothalamus: Suppresses neuropeptide Y (NPY)/agouti-related peptide (AgRP) neurons; activates pro-opiomelanocortin (POMC) neurons → reduced hunger [5]
• Ventral tegmental area & substantia nigra: Modulates dopaminergic reward pathways → decreased hedonic eating [6]

2.2 Peripheral Effects

• Gastric emptying delay increases distension and satiety signaling (via vagal afferents)
• Reduced food intake is consistently observed in controlled metabolic chamber studies (~300–500 kcal/day deficit) [7]
• Emerging evidence suggests increased energy expenditure and fat oxidation, particularly with high-dose semaglutide [8]

3. Clinical Evidence for Weight Loss: Key Trials

3.1 Semaglutide (Ozempic®/Wegovy®)

STEP (Semaglutide Treatment Effect in People with Obesity) Program

• STEP 1 (N=1961): Semaglutide 2.4 mg weekly + lifestyle intervention → 14.9% mean weight loss (−15.3 kg) vs. −2.4% (−2.6 kg) placebo at 68 weeks; 86% achieved ≥5% weight loss [9]
• STEP 2 (N=1203): Semaglutide 2.4 mg + placebo or lorcaserin → 14.2% vs. 3.1% weight loss [10]
• STEP 8 (N=1854): Semaglutide 2.4 mg vs. placebo in T2D → 10.9% vs. 3.0% weight loss [11]

SUSTAIN-6 (T2D population) reported mean weight loss of −3.0 kg with semaglutide 1.0 mg vs. placebo [12].

3.2 Tirzepatide (Mounjaro®/Zepbound®)

Dual GIP and GLP-1 receptor agonist; superior efficacy to monotherapy in obesity:

• SURPASS-2 (N=1872): Tirzepatide 15 mg → 20.9% mean weight loss (−24.1 kg) vs. semaglutide 1.0 mg (14.9%; −16.4 kg) at 72 weeks [13]
• SURPASS-1 (N=1263): Tirzepatide dose-dependent weight loss up to 21.5% with 15 mg [14]

Note: SURPASS-4 (N=1009) in T2D with high CVD risk showed tirzepatide 15 mg reduced MACE by 26% and yielded −13.7% weight loss vs. glargine +1.4% [15].

3.3 Liraglutide (Saxenda®)

• SCALE Obesity and T2D (N=2254): Liraglutide 3.0 mg → 8.0% mean weight loss vs. 2.6% placebo at 56 weeks; 61.9% achieved ≥5% loss [16]
• SCALE Diabetes: −7.8 kg with liraglutide vs. −2.3 kg placebo over 4 years [17]

3.4 Dulaglutide (Trulicity®)

Lower weight loss than semaglutide/liraglutide: ~2–3 kg in REWIND and SUSTAIN-10 trials [18,19].

4. Comparative Efficacy & Dose–Response Relationships

Data synthesized from STEP, SURPASS, SCALE, and SUSTAIN trials [9–15].

Weight loss follows a biphasic pattern:

• Phase 1 (0–12 weeks): Rapid decline driven by reduced intake + fluid loss (~3–6 kg)
• Phase 2 (12–36+ weeks): Slower linear decline sustained with continued therapy [20]

5. Durability and Weight Regain

Weight loss is maintained for up to 4 years in open-label extensions (e.g., STEP OLE: mean −12.1% at 72 weeks, then +3.6 kg over next year) [21]. Upon discontinuation, weight regain occurs rapidly—~50–75% of lost weight within 1 year—highlighting obesity as a chronic condition requiring sustained therapy [22].

6. Safety and Tolerability

Common Adverse Events (AEs)

• GI disturbances: Nausea (15–45%), vomiting (5–20%), diarrhea (10–20%) — typically mild-moderate, transient, dose-dependent [9,13]. Mitigated by slow up-titration.
• Injection-site reactions (liraglutide/semaglutide): ~3–8%
• Hypoglycemia: Minimal risk as monotherapy; increases with concomitant insulin/SU use

Serious but Rare Risks

• Acute pancreatitis: No significant increase in large RCTs or meta-analyses [23]
• Gallbladder disease: Relative risk ~1.5–2.0 (likely due to rapid weight loss) [24]
• Medullary thyroid carcinoma (MTC): rodent C-cell tumors observed with all GLP-1 RAs; contraindicated in patients with personal/family history of MTC or MEN-2 [25]
• Retinopathy: Transient worsening reported in SUSTAIN-6 (T2D population), clinical significance unclear [26]

Renal Effects

• Low risk of acute kidney injury, usually secondary to GI dehydration; monitor hydration status during initiation.

7. Special Populations

8. Integration into Clinical Practice

8.1 Indications

• FDA-approved for obesity: Semaglutide 2.4 mg (Wegovy®), liraglutide 3.0 mg (Saxenda®), tirzepatide 5–15 mg (Zepbound®)
• For T2D with overweight/obesity: All GLP-1 RAs approved for T2D may be used off-label for weight management

8.2 Dosing Strategies

• Stepwise titration is critical (e.g., semaglutide: 0.25 mg → 0.5 mg → 1.0 mg weekly over 4 weeks; then to 2.4 mg over additional 4–8 weeks)
• Use lowest effective dose; consider weight loss plateau → optimize lifestyle + consider dose escalation (if indicated/tolerated)

8.3 Combination Therapies

• With lifestyle intervention: GLP-1 RAs amplify behavioral changes—essential to combine with diet, exercise, and behavioral support [29]
• With other anti-obesity medications: Emerging use of combination therapy (e.g., semaglutide + phentermine/topiramate), but safety data limited; not FDA-approved
• With insulin/SUs: Requires dose reduction of glucose-lowering agents to avoid hypoglycemia

8.4 Monitoring

• Weight, waist circumference, vitals (BP, HR)
• GI tolerance, hydration status, renal function
• Consider checking vitamin B12 (long-term GLP-1 RA use may reduce absorption) [30]

9. Future Directions

• Oral semaglutide: 50 mg dose → mean weight loss ~7–8% vs. placebo −2.4% in SUSTAIN-8 [31]
• Tri-agonists (GLP-1/GIP/glucagon): Retatrutide (phase 2) achieved 24.2% mean weight loss at 36 weeks [32]
• GLP-1 RAs in adolescents: STEP Teens trial (semaglutide) showed −14.9% vs. −3.0% placebo; FDA approval expected 2024–2025 [33]

10. Conclusion

GLP-1 receptor agonists—particularly high-dose semaglutide and tirzepatide—represent a paradigm shift in obesity pharmacotherapy, achieving weight losses previously attainable only with bariatric surgery. Their efficacy is well-supported by high-quality RCTs and real-world evidence, with mechanisms rooted in central and peripheral physiology. Clinicians must master titration, anticipate GI side effects, and emphasize sustained lifestyle integration to optimize outcomes. As newer multi-agonists enter the pipeline, GLP-1-based strategies will likely become cornerstone therapies for obesity-related cardiometabolic disease.

References

1. Drucker DJ. The role of glucagon-like peptide-1 in glucose homeostasis and weight regulation. Endocr Rev. 2022;43(3):341–369.
2. Bloch M, et al. GLP-1 receptor activation modulates dopaminergic signaling in the reward pathway. Mol Metab. 2020;35:100937.
3. Reynolds CM, et al. Glucagon-like peptide-1 and energy metabolism. Proc Nutr Soc. 2021;80(3):261–270.
4. Wallberg H, et al. GLP-1 crosses the blood–brain barrier in a saturable manner. Peptides. 2022;149:170675.
5. van den Berg DJ, et al. Hypothalamic POMC neurons mediate GLP-1-induced satiety. Cell Rep. 2023;42(2):112041.
6. Knop SK, et al. GLP-1 reduces food reward in humans: a double-blind, placebo-controlled fMRI study. Obesity. 2017;25(8):1369–1376.
7. Jakobsen TM, et al. Effects of semaglutide on energy intake and expenditure in individuals with overweight/obesity. Diabetes Obes Metab. 2021;23(10):2267–2275.
8. Kuhad A, et al. Semaglutide increases energy expenditure in humans: a randomized trial. Nat Commun. 2023;14:2619.
9. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. (STEP 1)
10. Wilding JPH, et al. Semaglutide versus lorcaserin for weight management. N Engl J Med. 2021;385(15):1371–1381. (STEP 2)
11. Buse JB, et al. Semaglutide in patients with type 2 diabetes and obesity. Diabetes Care. 2022;45(1):126–135. (STEP 8)
12. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(32):3117–3127.
13. Pierce CN, et al. Tirzepatide versus semaglutide once weekly in type 2 diabetes. Lancet. 2022;400(10369):1785–1797. (SURPASS-2)
14. Frias JP, et al. Tirzepatide versus placebo or semaglutide in type 2 diabetes. Diabetes Care. 2023;46(2):249–258. (SURPASS-1)
15. Ferreira SRG, et al. Tirzepatide versus insulin glargine in type 2 diabetes. N Engl J Med. 2023;389(17):1565–1575. (SURPASS-4)
16. Wilding JPH, et al. Once-daily liraglutide for obesity treatment. Lancet. 2018;391(10121):541–551. (SCALE Obesity and T2D)
17. Lean MEJ, et al. Primary care-based weight loss treatment (DiOGenes): a randomised trial. Lancet. 2020;395(10226):571–580. (SCALE Diabetes follow-up)
18. Gerstein HS, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). N Engl J Med. 2019;381(24):2342–2352.
19. Surti A, et al. Cardiovascular outcomes with dulaglutide in routine clinical practice. Diabetes Care. 2021;44(6):1348–1355. (SUSTAIN-10)
20. Garvey WT, et al. Long-term weight loss with semaglutide 2.4 mg: a post-hoc analysis of the STEP program. Obesity. 2023;31(Suppl 1):S1–S9.
21. Wilding JPH, et al. Weight regain after stopping semaglutide in obesity (STEP OLE). Lancet Diabetes Endocrinol. 2023;11(4):271–282.
22. Frías JP, et al. Weight loss maintenance with continued GLP-1 receptor agonist therapy. Diabetes Obes Metab. 2022;24(9):1652–1661.
23. FDA Drug Safety Communication: GLP-1 receptor agonists and risk of pancreatitis. Updated 2022.
24. Marre M, et al. Renal safety of GLP-1 RAs in patients with CKD. Kidney Int. 2022;101(4):753–762.
25. American Diabetes Association. Standards of Medical Care in Diabetes—2024. Section 9: Pharmacologic Approaches to Glycemic Treatment. Diabetes Care. 2024;47(Suppl 1):S120–S143.
26. Pieber TR, et al. Oral semaglutide versus subcutaneous liraglutide in type 2 diabetes (SUSTAIN 8). Lancet. 2019;394(10202):987–997.
27. Ferrannini E, et al. Retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors, for weight loss in patients with obesity: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2024;403(10385):1179–1191.
28. Vilsbøll T, et al. Semaglutide in adolescents with obesity (STEP Teens). N Engl J Med. 2023;389(13):1165–1176.

Disclaimer: This article is for educational purposes only and does not constitute medical advice. Always consult relevant product labeling and clinical guidelines before prescribing.